DDIT3 and mature T-cell and NK-cell non-Hodgkin lymphoma: Smaller phase II studies in PTCL have also shown single-agent activity, with ORR around 40–50% (particularly in CD25+ cases), and early efforts have combined the drug with CHOP in frontline PTCL, establishing feasibility.